文献速递前列腺癌

前列腺多参数磁共振成像在活检阴性且前列腺特异性抗原升高男性中的阴性预测值:一项临床结局回顾性队列研究

Negative Predictive Value of Prostate Multiparametric Magnetic Resonance Imaging among Men with Negative Prostate Biopsy and Elevated Prostate Specific Antigen: A Clinical Outcome Retrospective Cohort Study.
PubMed 文献 · J Urol · 2019-06-12

该回顾性队列研究纳入2004至2009年间活检后行前列腺多参数磁共振成像的男性,评估其在长期随访(中位6.7年)中检测临床显著(Gleason 7或以上)前列腺癌的阴性预测值。在既往系统活检阴性的男性中,磁共振阴性者随访期间96%保持无临床显著前列腺癌,全队列总体阴性预测值为86%。结论认为前列腺多参数磁共振成像具有高临床阴性预测值。

要点

  • 既往活检阴性且磁共振阴性者,中位6.7年随访中96%无临床显著前列腺癌。
  • 全队列总体阴性预测值为86%,阳性预测值为54%。
  • 前列腺多参数磁共振成像具有高临床阴性预测值。

核心结论

  • 前列腺多参数磁共振成像具有高临床阴性预测值。
  • 在磁共振前活检阴性且磁共振阴性的男性中,中位6.7年随访时临床显著前列腺癌风险极低。

研究设计与样本

  • 经机构研究伦理委员会批准,利用癌症登记数据库和磁共振报告回顾性识别2004至2009年间活检后行前列腺多参数磁共振成像的男性。
  • 共纳入502次有既往活检的多参数磁共振成像扫描,其中121次来自既往系统活检阴性男性。
  • 磁共振序列2004至2005年为T2加权和动态对比增强序列,2006年起加入弥散加权成像。
  • 通过查阅后续病理结果、前列腺特异性抗原水平和电子病历评估截至2015年7月的临床结局。

主要发现

  • 121次既往系统活检阴性男性扫描中,中位前列腺特异性抗原为9.5 ng/dl,中位年龄60岁。
  • 中位随访6.7年(95%CI 2.6至10.7)时,73例磁共振阴性男性中70例(96%)保持无临床显著前列腺癌。
  • 全队列(不论磁共振前活检状态)总体阴性预测值为86%(范围80%至91%),阳性预测值为54%(范围52%至57%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We estimated the negative predictive value of prostate multiparametric magnetic resonance imaging to detect clinically significant (Gleason 7 or greater) prostate cancer at long-term followup (median 6.7 years, range 2.6 to 10.7), in men with negative biopsy findings before magnetic resonance imaging. We also assessed the diagnostic performance of multiparametric magnetic resonance imaging to detect clinically significant prostate cancer during this time. MATERIALS AND METHODS: Following Institutional Research Ethics Board approval we retrospectively identified men who underwent prostate multiparametric magnetic resonance imaging after biopsy between 2004 and 2009 using a cancer registry database and magnetic resonance imaging reports. Multiparametric magnetic resonance imaging sequences comprised T2-weighted and dynamic contrast-enhanced series from 2004 to 2005 with diffusion-weighted imaging from 2006 and thereafter. Clinical outcomes were assessed up to July 2015 by reviewing subsequent pathology results, prostate specific antigen levels and electronic patient records. The primary outcome was clinically significant prostate cancer diagnosis during followup. We also estimated the sensitivity, specificity, and positive and negative predictive values of all prostate multiparametric magnetic resonance imaging during this period. RESULTS: A total of 502 multiparametric magnetic resonance imaging scans with a prior biopsy were included in study. Of these scans 121 were done in men with a prior systematic biopsy negative for cancer. In these men median prostate specific antigen was 9.5 ng/dl and median age was 60 years. At a median followup of 6.7 years (95% CI 2.6 to 10.7) 70 of 73 (96%) men with negative multiparametric magnetic resonance imaging findings remained free of clinically significant prostate cancer. In this period the overall negative and positive predictive values of multiparametric magnetic resonance imaging were 86% (range 80% to 91%) and 54% (range 52% to 57%), respectively, in the entire cohort regardless of biopsy status before magnetic resonance imaging. CONCLUSIONS: Prostate multiparametric magnetic resonance imaging has high clinical negative predictive value. In men with a negative biopsy before magnetic resonance imaging and negative magnetic resonance imaging findings the risk of clinically significant prostate cancer was extremely low at a median of 6.7 years.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lo G, Burton KR, Haider MA, et al. Negative Predictive Value of Prostate Multiparametric Magnetic Resonance Imaging among Men with Negative Prostate Biopsy and Elevated Prostate Specific Antigen: A Clinical Outcome Retrospective Cohort Study. J Urol. 2019. PMID: 31188731. doi:10.1097/JU.0000000000000388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。